HUTCHMED (China) Limited (AIM: HCM)
Health Care · Pharmaceuticals · HK
£1.84
+1.10% today · -22.0% 1Y
HUTCHMED (China) Limited (AIM: HCM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.18B.
Over the last twelve months the share price has lost 22.0%, trading between 1.50 and 2.66.
Tweenvest scores HUTCHMED (China) Limited across four factors: quality 56/100, value 59/100, growth 66/100. Its strongest factor is growth.
HCM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.18B
- Revenue (TTM)
- $549.12M
- P/E
- 120.92
- EPS
- 0.02
- Dividend yield
- —
- Beta (5Y)
- 0.44
- 52-week high
- £2.66
- 52-week low
- £1.50
- Avg volume (3M)
- —
- Shares outstanding
- 869.07M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.